From: Midazolam sedation in palliative medicine: retrospective study in a French center for cancer control
Characteristics (N = 54) | n | % |
---|---|---|
Age (years) | ||
Median (range) | 56.9 | (25.6–85.7) |
Mean (standard deviation) | 56.9 | (13.1) |
Gender | ||
Female | 31 | 57.4% |
Male | 23 | 42.6% |
Medical supervision unit | ||
Palliative care | 17 | 31.5% |
Uro-digestive | 12 | 22.2% |
Breast | 10 | 18.5% |
General Oncology | 8 | 14.8% |
Upper aerodigestive tract | 5 | 9.3% |
Gynecology | 2 | 3.7% |
Primitive Tumor | ||
Breast | 11 | 20.4% |
Upper aerodigestive tract | 10 | 18.5% |
Lung | 6 | 11.1% |
Colon-rectum | 4 | 7.4% |
Œsophagus | 4 | 7.4% |
Soft tissue sarcoma | 4 | 7.4% |
Cervix | 2 | 3.7% |
Prostate | 2 | 3.7% |
Bladder | 2 | 3.7% |
Anal canal | 1 | 1.9% |
Lymphoma | 1 | 1.9% |
Bone | 1 | 1.9% |
Ovary | 1 | 1.9% |
Skin | 1 | 1.9% |
Kidney | 1 | 1.9% |
Biliary | 1 | 1.9% |
Unknown | 2 | 3.7% |
Indication for sedation | ||
Immediate risk of death | 25 | 46.3% |
Respiratory distress | 18 | 33.3% |
Hemorrhage | 5 | 9.3% |
Hemodynamic shock | 2 | 3.7% |
Refractory symptoms a | 26 | 48.1% |
Respiratory disorders | 10 | 18.5% |
Agitation and confusion | 9 | 16.7% |
Anxiety | 4 | 7.4% |
Pain | 2 | 3.7% |
Bleeding | 1 | 1.9% |
Asthenia | 1 | 1.9% |
Status epilepticus | 1 | 1.9% |
Existential suffering | 3 | 5.6% |